Related references
Note: Only part of the references are listed.The Peroxisome Proliferator-Activated Receptor γ Agonist Rosiglitazone Ameliorates Murine Lupus by Induction of Adiponectin
Tamar Aprahamian et al.
JOURNAL OF IMMUNOLOGY (2009)
TNF-alpha inhibition reduces renal injury in DOCA-salt hypertensive rats
Ahmed A. Elmarakby et al.
AMERICAN JOURNAL OF PHYSIOLOGY-REGULATORY INTEGRATIVE AND COMPARATIVE PHYSIOLOGY (2008)
Effect of the addition of rosiglitazone to metformin or sulfonylureas versus metformin/sulfonylurea combination therapy on ambulatory blood pressure in people with type 2 diabetes: A randomized controlled trial (the RECORD study)
Michel Komajda et al.
CARDIOVASCULAR DIABETOLOGY (2008)
Sex differences in the pressor response to angiotensin II when the endogenous renin-angiotensin system is blocked
Julio C. Sartori-Valinotti et al.
HYPERTENSION (2008)
Systemic lupus erythematosus and cardiovascular disease
J. Frostegard
LUPUS (2008)
Atherosclerosis and systemic lupus erythematosus: the role of altered lipids and of autoantibodies
B. H. Hahn et al.
LUPUS (2008)
Mycophenolate mofetil administration reduces renal inflammation, oxidative stress, and arterial pressure in rats with lead-induced hypertension
Yanauri Bravo et al.
AMERICAN JOURNAL OF PHYSIOLOGY-RENAL PHYSIOLOGY (2007)
Effects of thiazolidinediones on blood pressure
Thomas D. Giles et al.
CURRENT HYPERTENSION REPORTS (2007)
Present concepts and outlook: Function of proliferator-activated receptors (PPARs) for future peroxisome pathogenesis, progression, and therapy of cancer
P. Sertznig et al.
JOURNAL OF CELLULAR PHYSIOLOGY (2007)
Synergistic vascular protective effects of combined low doses of PPARα and PPARγ activators in angiotensin II-induced hypertension in rats
C. De Ciuceis et al.
BRITISH JOURNAL OF PHARMACOLOGY (2007)
Prevention of angiotensin II-induced cardiac remodeling by angiotensin-(1-7)
Justin L. Grobe et al.
AMERICAN JOURNAL OF PHYSIOLOGY-HEART AND CIRCULATORY PHYSIOLOGY (2007)
Endothelin A receptor blockade reduces diabetic renal injury via an anti-inflammatory mechanism
Jennifer M. Sasser et al.
JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY (2007)
PPAR-gamma activation inhibits angiotensin II synthesis, apoptosis, and proliferation of mesangial cells from spontaneously hypertensive rats
Shai Efrati et al.
NEPHRON EXPERIMENTAL NEPHROLOGY (2007)
Insulin resistance and obesity in a mouse model of systemic lupus erythematosus
Michael J. Ryan et al.
HYPERTENSION (2006)
Protection of the kidney by thiazolidinediones: An assessment from bench to bedside
P. A. Sarafidis et al.
KIDNEY INTERNATIONAL (2006)
Rosiglitazone reduces microalbuminuria and blood pressure independently of glycemia in type 2 diabetes patients with microalbuminuria
George L. Bakris et al.
JOURNAL OF HYPERTENSION (2006)
Prevention of cardiovascular disease in patients with rheumatic diseases
Robyn Domsic et al.
BEST PRACTICE & RESEARCH IN CLINICAL RHEUMATOLOGY (2006)
Inflammatory modulation of PPARγ expression and activity
MB Crosby et al.
CLINICAL IMMUNOLOGY (2006)
Modification of hypertension and hypercholesterolaemia in patients with systemic lupus erythematosus: a quality improvement study
MB Urowitz et al.
ANNALS OF THE RHEUMATIC DISEASES (2006)
The renin-angiotensin system in lupus: physiology, genes and practice, in animals and humans
V. Teplitsky et al.
LUPUS (2006)
Thiazolidinediones expand body fluid volume through PPARγ stimulation of ENaC-mediated renal salt absorption
YF Guan et al.
NATURE MEDICINE (2005)
Role of endothelin in mediating tumor necrosis factor-induced hypertension in pregnant rats
BBD LaMarca et al.
HYPERTENSION (2005)
Collecting duct-specific deletion of peroxisome proliferator-activated receptor γ blocks thiazolidinedione-induced fluid retention
H Zhang et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2005)
SLE, atherosclerosis and cardiovascular disease
J Frostegård
JOURNAL OF INTERNAL MEDICINE (2005)
PPARγ agonist rosiglitazone improves vascular function and lowers blood pressure in hypertensive transgenic mice
MJ Ryan et al.
HYPERTENSION (2004)
Rosiglitazone activates renal sodium- and water-reabsorptive pathways and lowers blood pressure in normal rats
J Song et al.
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS (2004)
Clinical and histopathological progression of lesions in lupus-prone (NZB x NZW) F1 mice
R Burnett et al.
EXPERIMENTAL AND TOXICOLOGIC PATHOLOGY (2004)
Improvement of insulin resistance by troglitazone ameliorates cardiac sympathetic nervous dysfunction in patients with essential hypertension
K Watanabe et al.
JOURNAL OF HYPERTENSION (2004)
Rosiglitazone improves, while glibenclamide worsens blood pressure control in treated hypertensive diabetic and dyslipidemic subjects via modulation of insulin resistance and sympathetic activity
CA Yosefy et al.
JOURNAL OF CARDIOVASCULAR PHARMACOLOGY (2004)
Pioglitazone prevents hypertension and reduces oxidative stress in diet-induced obesity
AD Dobrian et al.
HYPERTENSION (2004)
Autoantibody explosion in systemic lupus erythematosus: More than 100 different antibodies found in SLE patients
Y Sherer et al.
SEMINARS IN ARTHRITIS AND RHEUMATISM (2004)
Angiotensin inhibition reduces glomerular damage and renal chemokine expression in MRL/lpr mice
GP De Lema et al.
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS (2003)
Effect of peroxisome proliferator-activated receptor-alpha and -gamma activators on vascular remodeling in endothelin-dependent hypertension
M Iglarz et al.
ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY (2003)
Structure, endothelial function, cell growth, and inflammation in blood vessels of angiotensin II-infused rats -: Role of peroxisome proliferator-activated receptor-γ
QN Diep et al.
CIRCULATION (2002)
Peroxisome proliferator-activated receptor gamma agonists - Potential use for treating chronic inflammatory diseases
JC Oates et al.
ARTHRITIS AND RHEUMATISM (2002)
Efficacy of mycophenolate mofetil in patients with diffuse proliferative lupus nephritis
TM Chan et al.
NEW ENGLAND JOURNAL OF MEDICINE (2000)
Comparative effects of pioglitazone, glibenclamide, and voglibose on urinary endothelin-1 and albumin excretion in diabetes patients
T Nakamura et al.
JOURNAL OF DIABETES AND ITS COMPLICATIONS (2000)
Share Paper
